Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
JERUSALEM, April 1, 2026 /PRNewswire/ — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); (“Scinai” or the “Company”), a biopharmaceutical company operating a dual…
